Home Forums > ME/CFS News and Research > ME/CFS News and Research > BioMedical ME/CFS Research >
Articles on Montoya and Mark Davis's Cytokine work
Discussion in 'BioMedical ME/CFS Research' started by Adrian, Nov 2, 2017.
montoya
Adrian Administrator Staff Member
Montoya, Davis et al published their paper on cytokine signatures for ME in July.
Cytokine signature associated with disease severity in chronic fatigue syndrome patientsPNAS 2017 114 (34) E7150-E7158; published ahead of print July 31, 2017, doi:10.1073/pnas.1710519114
http://www.pnas.org/content/114/34/E7150.full
Now there has been a letter/article in response in PNAS that criticizes their methodology. Unfortunately its not public access
Cytokine signature in chronic fatigue syndrome
Megan E. Roerink, Matthew Buckland, Andrew R. Lloyd, and Jos W. M. van der Meer,
One of the major findings in the publication by Montoya et al. (1) on cytokine signatures in chronic fatigue syndrome is elevation of circulating TGF-β in patients with chronic fatigue syndrome (CFS). Unfortunately, the materials and methods of ref. 1 do not give much information on how the controls were recruited, and how the blood samples …
And then a reply from Mark Davis
Reply to Roerink et al: Methods for recruitment, serum separation, and storage were the same for patients and controls
Jose G. Montoya, Holden T. Maecker, Yael Rosenberg-Hasson and Mark M. Davis
Roerink et al. (1) raise important and potential methodological biases that could have accounted for our finding regarding elevated TGF-β levels in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (2). Here, we provide additional information as requested by Roerink et al. (1) that supports that the elevation of TGF-β in patients with ME/CFS is most likely to be rooted in the biology of ME/CFS and not due to methodological issues. As stated in the materials and methods of ref. 2, both patients and controls were recruited from Northern California from March
Adrian, Nov 2, 2017
adambeyoncelowe, inox, Woolie and 16 others like this.
Valentijn Guest
Adrian said: ↑
Full text of the letter is at http://sci-hub.io/10.1073/pnas.1714011114 . Basically, they claim that they screwed up in the past and later decided their results weren't significant after all. I think this might be the same group who published a "nothing to see here" biomedical paper recently after sitting on it for years:
The major pitfall here is contamination of the plasma by platelet-derived TGF-β. In an otherwise carefully controlled study of patients with CFS, we found that the use of two centrifuges with a different g-force (at the same centrifugation speed) led to markedly different TGF-β values, reflected by differences in the platelet marker, P-selectin, which showed a strong correlation with TGF-β.
Full text of the author response is at http://sci-hub.io/10.1073/pnas.1714692114 They respond with a lot of the details of their methodology, basically establishing that they know what they're doing, unlike other groups . And I think this bit addresses concerns regarding different batch processing variability:
For the day of the cytokine assay, matched sets of ME/CFS cases and healthy controls were always mixed in all plates to reduce confounding case status with plate artifacts. In summary, patients with ME/CFS and controls were treated identically in terms of recruitment and sera handling protocols. Thus, it is more likely that TGF-β differences between patients with ME/CFS and controls in our study are due to biological, rather than methodological, differences between the two groups.
And they also refute the "nothing to see here", which is pretty relevant. If results were down to processing differences, it would be unlikely that random differences would consistently favor abnormally elevated results for ME patients:
GF-β has also been found elevated in patients with ME/CFS in five other studies (3–7). In one study (5), TGF-β bioactivity was found higher in patients with ME/CFS than in controls and patients with major depression, systemic lupus erythematous, relapsing/remitting multiple sclerosis, and chronic progressive multiple sclerosis as well.
Valentijn, Nov 2, 2017
adambeyoncelowe, inox, Inara and 18 others like this.
Sean Senior Member (Voting Rights)
I do love it when the serious pros ride into town, and show the amateurs how it is done.
Sean, Nov 2, 2017
adambeyoncelowe, Little Bluestem, Robert 1973 and 9 others like this.
Sid Senior Member (Voting Rights)
The reply is reassuring.
Sid, Nov 2, 2017
adambeyoncelowe, Inara, Ron and 3 others like this.
Simon M Senior Member (Voting Rights)
Briefly: Roerink et al argued that methodological issues with blood plasma processing could account for the finding of higher cytokine TGF-beta in patients. Montoya et al responded that they looked at blood serum, not plasma, as their paper had spelt out.
Whatever the motivations behind the letter, I do like such methodological geek-sparring, which I think is good for keeping science honest. The tone of the initial letter was polite and I was like that it suggested specific ways to check that the TGF finding wasn't down to contamination from platelets (that also produce TGF-beta).
Montoya and colleagues don't respond to this specific point, instead emphasising that while the critical letter highlights issues with plasma, the Montoya paper used serum as they spelt out throughout the paper. This is very important, I think, not to mention a blunder by the critical authors. It's all down to clotting and the difference between serum and plasma:
Differences between Serum and Plasma
Serum is the fluid you see leaking out of the wounds, it's what's left over from blood after it clots. Plasma is slightly different: it's the fluid you get left with when the red and white blood cells, and platelets are separated away by centrifuging (which is why the first letter gets so excited about centrifugal details). You have to add anti-clotting agents to get plasma.
Key difference here is that clotting takes place to generate serum, which takes platelets out of the equation as they form the clots. Whether or not that removes all possibility of platelet-derived TGF-beta contamination being a factor, I don't know. But it does mean that the letter from Roerink and colleagues is largely barking up the wrong tree.
Simon M, Nov 2, 2017
inox, Inara, alex3619 and 26 others like this.
Jonathan Edwards Senior Member (Voting Rights)
There may be a problem with serum too:
(the second plasmin step is not relevant)
Nat Med. 1995 Sep;1(9):932-7.
Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin.
Grainger DJ1, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC.
Transforming growth factor beta 1 (TGF-beta 1) is a platelet-derived cytokine involved in both normal wound healing and scarring. We show that human platelets contain two pools of latent TGF-beta 1, which constitute more than 95% of the total TGF-beta assayed in whole platelets. During clotting, one pool, the large latent TGF-beta complex consisting of latent TGF-beta binding protein (LTBP), the latency-associated peptide (LAP) and the 25-kD mature TGF-beta 1 dimer is released into the serum. A second pool, which contains LAP but not LTBP, is retained in the clot, but can be released by RGD peptide. When the clot is dissolved by plasmin this bound TGF-beta 1 is gradually activated and released. If similar mechanisms operate in vivo, the clot will act as a slow-release capsule of TGF-beta 1 activity during wound healing.
But if the Montoya samples were all collected the same way and run on the same plates they should be OK.
Like Simon, I think it is good to have this sort of critique going on. You can never get enough of methodological cross-checking. Problems arise so easily.
Jonathan Edwards, Nov 7, 2017
Hutan, adambeyoncelowe, inox and 7 others like this.
Esther12 Senior Member (Voting Rights)
Just found this short summary in nature that I thought would be worth posting: https://www.nature.com/articles/d41586-017-02105-4
Esther12, Sep 10, 2018
MEMarge, adambeyoncelowe and inox like this.